To block the androgen receptor (AR) in patients with advanced prostate cancer, current guidelines suggest a combined therapy with second-generation antiandrogens such as abiraterone, apalutamide, enzalutamide, or darolutamide [2,3]. This evidence concerns the gene AR and Familial prostate cancer.